Solana Company Stock Price, News & Analysis

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced a public offering of 1,204,375 shares of common stock at $8.00 per share, aiming to raise approximately $9.6 million in gross proceeds. The offering will close around November 12, 2021, subject to customary conditions. The company plans to use the net proceeds for operations, working capital, and general corporate purposes. Ladenburg Thalmann & Co. Inc. serves as the sole book-running manager for the offering, which is conducted under an effective shelf registration statement.

Helius Medical Technologies (HSDT) announced a proposed underwritten public offering of its common stock. The company will sell all shares, with a potential additional 15% option for the underwriter. Proceeds from the offering will be directed towards funding operations, working capital, and general corporate purposes. This offering is contingent on market conditions and follows a shelf registration statement effective since February 6, 2020. Ladenburg Thalmann & Co. Inc. is the sole book-running manager for this offering.

Helius Medical Technologies (Nasdaq: HSDT) has launched its Therapeutic Experience Program (TEP) in partnership with NYU Langone Health to assess adherence to PoNS therapy in patients with multiple sclerosis (MS). The study aims to evaluate the effectiveness of the PoNS device in improving gait deficits, enrolling 50-60 patients across 10-12 Centers of Excellence in the U.S. Enrollment is expected to begin in Q4 2021 and continue through mid-2022. This program is pivotal for understanding the relationship between treatment adherence and therapeutic outcomes in a real-world setting.

Helius Medical Technologies (Nasdaq:HSDT) announced receiving market authorization from the Australian Therapeutic Goods Administration for its PoNS device as a Class IIa medical device. This authorization allows PoNS to be sold in Australia to aid patients in improving balance and gait when used alongside therapeutic exercises. The company is preparing for commercialization in Australia, marking the third country to authorize PoNS, following the U.S. and Canada. CEO Dane C. Andreeff expressed enthusiasm for this development.

Helius Medical Technologies (NASDAQ: HSDT) plans to release its third quarter 2021 financial results on November 10, 2021, after market close. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 5:00 PM ET to discuss results and company updates. The Portable Neuromodulation Stimulator (PoNS®), Helius’s first commercial product, aims to assist patients with gait deficits from conditions like multiple sclerosis and traumatic brain injuries. PoNS® is currently authorized in the U.S. and Canada for specific medical uses.

Helius Medical Technologies (HSDT) announced that its compensation committee has approved equity awards for six new employees as part of its 2021 Inducement Plan. Effective October 28, 2021, these individuals will receive options to purchase a total of 22,000 shares of Class A common stock at an exercise price of $14.20 each. The options are set to vest over four years, contingent on the continuation of their employment. Helius focuses on neurotech solutions aimed at improving the lives of those affected by neurological diseases.

Helius Medical Technologies (Nasdaq: HSDT) announced that CEO Dane C. Andreeff will present at the Dawson James Small Cap Growth Conference on October 21, 2021, from 11:00-11:20 AM ET. Interested parties can access the live webcast via this link, which will also be available for 30 days post-event. Helius focuses on neurological wellness, developing the Portable Neuromodulation Stimulator (PoNS™), an FDA-authorized device for treating gait deficits related to multiple sclerosis and traumatic brain injury.

Helius Medical Technologies (HSDT) announced that CEO Dane C. Andreeff will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 1:35 PM ET. The event will be available via live webcast and archived on their website for 30 days. Helius focuses on neurological wellness and aims to develop non-invasive technologies, including its Portable Neuromodulation Stimulator (PoNS™), designed for treating gait deficits and balance issues associated with neurological conditions.

Helius Medical Technologies (Nasdaq:HSDT) announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Buckman, who brings over 30 years of experience in the medical device sector, will serve as Chair of the Audit Committee and a member of the Compensation and Nominating & Governance Committees. He is currently President, North America for LivaNova and has held leadership roles in various medical device companies. His expertise is expected to enhance Helius' growth, particularly with its novel treatment approaches for chronic neurological conditions.